Prospect of Using Cell Product for the Therapy of Skin Defects in Diabetes Mellitus

A. P. Lykov; N. A. Bondarenko; O. V. Poveshchenko; T. V. Miller; A. F. Poveshchenko; M. A. Surovtseva; N. P. Bgatova; V. I. Konenkov

doi:10.1007/s10517-017-3970-0

Prospect of Using Cell Product for the Therapy of Skin Defects in Diabetes Mellitus

Autores: Lykov A.¹^,2, Bondarenko N.¹^,2, Poveshchenko O.¹^,2, Miller T.¹, Poveshchenko A.¹^,2, Surovtseva M.¹^,2, Bgatova N.¹, Konenkov V.¹
Afiliações:
1. Research Institute of Clinical and Experimental Lymphology
2. E. N. Meshalkin Research Institute of Circulatory Pathology, Ministry of Health of the Russian Federation
Edição: Volume 164, Nº 2 (2017)
Páginas: 266-268
Seção: Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
URL: https://journals.rcsi.science/0007-4888/article/view/239545
DOI: https://doi.org/10.1007/s10517-017-3970-0
ID: 239545

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Estatísticas

Resumo

The effectiveness of autologous cell product in the therapy of skin burn wounds was studied in C57B1/6 male mice against the background of streptozotocin-induced diabetes mellitus. In animals with and without modeled diabetes mellitus, significant decrease in skin defect area was observed after single administration of the cell product (bone marrow multipotent mesenchymal stromal cells, fibroblasts or media conditioned by these cells).